Swiss proteomics firm Biognosys said this week it has raised CHF2.7 million ($3 million) in a Series A funding round.
The money will be used to expand the company's targeted proteomics platforms and enable pursuit of additional industry collaborations, CEO Oliver Rinner told ProteoMonitor.
More specifically, Rinner said, the company is interested in tools for increasing multiplexing and throughput of targeted proteomics assays. He cited in particular the SWATH technology devised in the lab of Ruedi Aebersold of the Swiss Federal Institute of Technology Zurich, which Rinner helped develop. SWATH is a novel mass spec technique for monitoring fragment ions over a large precursor range, enabling high-throughput selected reaction-monitoring-style mass spec experiments.
The technique "is very interesting to us," Rinner said. "It fits perfectly into our capabilities in terms of high-throughput assay design."
He added that Biognosys is "involved with the Aebersold lab, especially in developing the software aspects" of the technology.
Aebersold developed SWATH using AB Sciex's TripleTOF 5600 instrument, which, Aebersold told ProteoMonitor upon introducing the method at the American Society for Mass Spectrometry annual meeting in June, has the combination of speed, sensitivity, and dynamic range needed to make the technique work (PM 6/10/2011).
Biognosys does not currently own a TripleTOF 5600, Rinner said, but, he said, it has access to one.
Participants in the round include Hellmut Kirchner, the co-founder of venture fund Techno Venture Management; Redalpine Capital I, which led Biognosys' seed funding in 2009; ZKB, the venture arm of Cantonal Bank of Zurich; Syngenta Ventures; and private investors.
Biognosys was spun out of the Swiss Federal Institute of Technology in 2008. According to its website its customers include Novartis, Pfizer, Integrated Diagnostics, and Philips.
Have topics you'd like to see covered in ProteoMonitor? Contact the editor at abonislawski [at] genomeweb [.] com.